Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nicholas J. DePolo"'
VSV-G Pseudotyped Lentiviral Vector Particles Produced in Human Cells Are Inactivated by Human Serum
Autor:
Philip Lee Sheridan, Nicholas J. DePolo, Sybille L. Sauter, Kay Townsend, Joyce D. Reed, Thomas W. Dubensky, Douglas J. Jolly
Publikováno v:
Molecular Therapy. 2:218-222
Lentiviral vectors transduce dividing and postmitotic cells and thus are being developed toward therapies for many diseases affecting diverse tissues. One essential requirement for efficacy will be that vector particles are resistant to inactivation
Autor:
James E. McCormack, Nancy Sajjadi, Thomas W. Dubensky, James G. Respess, Joanne O'Dea, Trung K. Phuong, Carlos E. Ibanez, Judith Greengard, Philip Lee Sheridan, Margaret Dow Moore, Daniel J. de la Vega, Sybille L. Sauter, Kay Townsend, Kathy Nguyen, David A. Driver, Douglas J. Jolly, Andrea Lynn, Nicholas J. DePolo, Mordechai Bodner, Stephen M. W. Chang
Publikováno v:
Molecular Therapy. 2(3):262-275
For many applications, human clinical therapies using retroviral vectors still require many technological improvements in key areas of vector design and production. These improvements include higher unprocessed manufacturing titers, complement-resist
Autor:
Nicholas J. DePolo, Mordechai Bodner, Douglas J. Jolly, Cataline E. Harkleroad, Krishna K. Murthy, Judith Greengard, Thomas W. Dubensky, Carol Anderson, Andrew T. Watt
Publikováno v:
Journal of virology. 73(8)
The ability to deliver genes as therapeutics requires an understanding of the vector pharmacokinetics similar to that required for conventional drugs. A first question is the half-life of the vector in the bloodstream. Retroviral vectors produced in
Autor:
Nicholas J. DePolo, Darlene Martineau, Leila Akbarian, Michael J. Irwin, Stephanie Maifert, Nancy Sajjadi, John F. Warner, Kay Townsend, Will Lee, James E. McCormack, Douglas J. Jolly
Publikováno v:
Human gene therapy. 8(10)
Replication-incompetent retroviruses have been employed as gene therapy vectors in experimental settings for more than a decade. More recently, these vectors have been tested in the clinic as immunotherapeutic agents and anticancer agents. One potent
Autor:
James Hanlon, James E. McCormack, Edgar Kamantigue, Mary Petrowski, Steven J. Mento, Nancy Sajjadi, Douglas J. Jolly, Nicholas J. DePolo, Darlene Martineau, Wolfgang M. Klump
Publikováno v:
Human gene therapy. 8(10)
Gene delivery via murine-based recombinant retroviral vectors is currently widely used in gene therapy clinical trials. The vectors are engineered to be replication defective by replacing the structural and nonstructural genes of a cloned infectious
Autor:
Nicholas J. Depolo, John J. Holland
Publikováno v:
The Journal of general virology. 67
Summary Multiply cloned variants of vesicular stomatitis virus (VSV) were found to generate/amplify defective interfering (DI) particles at a rate greatly exceeding the rates normally observed for wild-type VSV (or for other mutants of VSV). A single
Autor:
Scott VandePol, Cecilio López-Galíndez, Juan Ortín, Pilar Pérez-Breña, Esteban Domingo, Rafael Nájera, Agustín Portela, John J. Holland, David A. Steinhauer, Juan Carlos de la Torre, Francisco Sobrino, Nieves Villanueva, Encarnación Martínez-Salas, Nicholas J. Depolo
Publikováno v:
Scopus-Elsevier
We review evidence that cloned (or uncloned) populations of most RNA viruses do not consist of a single genome species of defined sequence, but rather of heterogeneous mixtures of related genomes (quasispecies). Due to very high mutation rates, genom